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Abstract α-Synuclein, an abundant and conserved presynap-
tic brain protein, is implicated as a critical factor in
Parkinson’s disease (PD). The aggregation of α-synuclein is
believed to be a critical event in the disease process. α-
Synuclein is characterized by a remarkable conformational
plasticity, adopting different conformations depending on the
environment. Therefore, it is classified as an “intrinsically
disordered protein.” Recently, a debate has challenged the
view on the intrinsically disordered behavior of α-synuclein
in the cell. It has been proposed that α-synuclein is a stable
tetramer with a low propensity for aggregation; however, its
destabilization leads to protein misfolding and its aggregation
kinetics. In our critical analysis, we discussed about major
issues: (i) why α-synuclein conformational behavior does not
fit into the normal secondary structural characteristics of pro-
teins, (ii) potential amino acids involved in the complexity of
misfolding in α-synuclein that leads to aggregation, and (iii)
the role of metals in misfolding and aggregation. To evaluate
the above critical issues, we developed bioinformatics models
related to secondary and tertiary conformations,
Ramachandran plot, free energy change, intrinsic disordered
prediction, solvent accessibility, and FoldIndex pattern. To the
best of our knowledge, this is a novel critical assessment to
understand the misfolding biology of synuclein and its rele-
vance to Parkinson’s disease.
Keywords α-Synuclein .Aggregation . Parkinson’s disease .
Misfolding . Conformation .Metals
Introduction
The discovery of α-synuclein in 1997 provided a new dimen-
sion in understanding the significance of α-synuclein to neu-
rodegenerative diseases particularly Parkinson’s disease (PD)
[1]. The discovery was followed rapidly by a report identify-
ing full-length α-synuclein in Lewy bodies (LB) from post-
mortem brain tissue of sporadic Parkinson cases [2]. However,
further studies revealed that α-synuclein is the predominant
protein in LB in sporadic as well as in familial PD indicating
that the protein is actively sequestered into these inclusions
[3]. Another familial form of PD is linked to an α-synuclein
gene mutation causing an alanine to proline substitution at
position 30 (A30P) [4]. Also, a novel α-synuclein gene mu-
tation causing the substitution of glutamate to lysine at residue
46 (E46K) is discovered in Spanish kindred with familial PD
[5]. Further, α-synuclein gene mutation causing substitution
of alanine for threonine at position 53 (A53T) presents a
higher fibril formation rate which is considered to contribute
to early onset PD [6]. Taken together, these findings provided
strong evidence that α-synuclein plays a pivotal role in the
pathogenesis of PD, despite the fact that most cases of PD
cannot be traced to amutation in theα-synuclein gene. Further,
Puschmann et al. [7] hypothesized that special pediatric dis-
ease, like myoclonus epilepsy type I, familial and sporadic
parkinsonism, and dementia phenotypes, are found to be
associated with duplications, triplications, and possibly higher
order multiplications of the α-synuclein (SNCA) gene. The
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above hypothesis is supported by the distribution of afflicted
family members within the pedigree and by genealogical
information [7]. Biskup et al. [8] reviewed mutations in sev-
eral causative genes that are associated to monogenic forms of
the disorder. Point mutations, duplications, and triplications in
theα-synuclein gene are known to cause a rare dominant form
of PD in families, while mutations in the parkin gene, DJ-1,
PINK1, and ATP13A2 are attributed to cause autosomal re-
cessive parkinsonism of early onset. These monogenic vari-
ants are important tools in identifying cellular pathways and
also provide an insight on the molecular pathogenesis of
sporadic PD. Now it is clear that these genes play a role in
the etiology of the common sporadic form of PD through
synuclein [8].
Besides understanding how these mutations induce α-
synuclein over expression, the greatest challenge is to under-
stand the aggregation behavior ofα-synuclein. Protein folding
is essential for life’s many functions; it is not therefore too
surprising that protein misfolding can lead to various diseases
[9]. Recent advances may demonstrate that an increasing
number of disorders are related to protein misfolding and
aggregation. The term “misfolding” is used to describe con-
formational changes that result in a protein acquiring a suffi-
cient number of persistent nonnative interactions to affect its
overall architecture and/or its properties in a biologically
significant manner [9]. Experimental and theoretical studies
have, however, provided a resolution of this apparent paradox.
It is now evident that the folding process does not involve a
series of mandatory steps between specific partially folded
states, but rather a stochastic search of the many conforma-
tions accessible to a polypeptide chain [10–12]. The aggrega-
tion kinetics of α-synuclein is multifaceted passing through
monomer, oligomer, protofibrils, and aggregates. The folding
and misfolding behavior of α-synuclein is unique and beyond
protein folding and thermodynamics principles. The
misfolded α-synuclein undergoes folding when bound to lipid
moiety of membranes, thus leading to hypothesize the func-
tional ability of α-synuclein in signal transduction. This pro-
vided new understanding on the functional role ofα-synuclein
as a function of folding concept. In the present paper, we
would emphasize on the mechanisms of misfolding behavior
of α-synuclein and its aggregation propensity and whether
correcting misfolding can be of therapeutic relevance and an
application of bioinformatics models to understand folding
complexity of synuclein is suggested.
α-Synuclein Secondary Structure
α-Synuclein is a relatively small (140 amino acids), natively
unfolded protein, exhibiting a random coil secondary structure
in normal physiological conditions [10, 11]. At neutral pH, it
is calculated to have 24 negative charges (15 of which are
located in the last third of protein sequence) leading to a strong
electrostatic repulsion, which contributes to the lack of folding
of α-synuclein [10, 11]. Natively unfolded proteins possess
“turn-out” responses to changes in the environment, as their
structural complexities increase at high temperature or at
extreme pH [10, 11]. They are very flexible, but might adopt
relatively rigid conformations in the presence of natural li-
gands [10, 11]. For example, α-synuclein is shown to adopt
mostly α-helical secondary structure upon association with
small unilamellar vesicles or detergent micelle surfaces [10,
11].
Tertiary Structural Details of α-Synuclein
α-Synuclein being an unfolded protein has posed problems to
structural biologists to understand its 3D structure. Both NMR
and crystallography studies have faced problems as α-
synuclein tends to aggregate quickly thus making the 3D
understanding of its conformation difficult. However, struc-
tural biologists solved the partial conformation details of α-
synuclein using NMR at freezing temperatures and solid-state
models [13].
Recent NMR studies showed that α-synuclein fibrils from
the PD-related A53T mutant of α-synuclein fibrils contain
regions with increased mobility and structural elements dif-
ferent from beta-strand character, in addition to the rigid beta-
sheet-rich core region. But in the wild-type α-synuclein, the
C-terminus is found to be flexible and unfolded, whereas the
main core region is highly rigid and rich in beta-sheets. These
results provided insight that a disease-related mutant of α-
synuclein differs in both aggregation kinetics and fibril struc-
ture [13]. Further, Heise et al. [13] showed that oligomers or
protofibrils adopting the cross-beta-sheet structure is the char-
acteristic of fibrillating proteins and these conformations are
assumed to be the cytotoxic species.
Further, Bertoncini et al. [14] through NMR studies
showed that the spin-labeled monomers would have a reduced
shielding effect between different domains of the molecule
due to the accelerated aggregation kinetics in A53T α-
synuclein. This may result in a more efficient exposure of
the C-terminal region leading to the more facile association of
neighboring molecules. Also the accelerated aggregation ki-
netics itself may result in a polymorphic pattern of assembly
as observed by an extended β-sheet core region. But in the
fibrils of both the mutant and the wild-type α-synuclein, the
C-terminus extending from at least residue 107 is flexible,
whereas the N-terminus extending from residue 22 is rigid.
All together the data provided important information on the
effect of altered aggregation properties on the fibril morphol-
ogy mutant of α-synuclein. This data is crucial in understand-
ing protein misfolding in disease condition.
Vilar et al. [15] based on NMR data and other data from
literature proposed a folding pattern in the core ofα-synuclein
fibrils. The proposed folding conformation has a five-layered
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β1-loop–β2-loop–β3-loop–β4-loop–β5-loop-sandwich
model. The five layers in parallel are generated when incor-
porated into a protofilament of a fibril. Besides in the straight
fibril type, two protofilaments align with each other to form a
fibril that can self-align again by itself. But in the twisted
fibrils, two protofilaments twist along each other. All these
models indicated that multiple protofilament packing is pos-
sible. Further, the comparative analysis indicated that the two
packings of straight and twisted fibrils also require different
filament interactions. Further, a comparative analysis between
the beta-sheet secondary structural elements of the fibrils and
the protein sequences indicates that the deletion of residues
74–84 in mammalian α-synuclein interferes with the fibril
formation, because these residues constitute beta-strand in
the fibrils. These data provided insight that amino acid se-
quence and layered folding pattern have influence on α-
synuclein folding behavior.
Further, Wu et al. [16] characterized the conformational
properties of natively unfolded human and mouse α-
synuclein. Human α-synuclein is highly homologous in ami-
no acid sequence to mouse α-synuclein. The mouse α-
synuclein is known to aggregate more rapidly than human
α-synuclein. They also made novel studies using NMR on
both α-synuclein at supercooled temperatures (263 K). The
studies indicated that both α-synuclein are natively unfolded
at low temperature. Further, they have found different propen-
sities to secondary conformation in synuclein. Mouse α-
synuclein showed a higher propensity to form helical confor-
mation around the C-terminal and also the loss of transient
long-range contacts from the C- to the N-terminal end.
Besides, mouse α-synuclein showed the lack of back-
folding from the C-terminal end to the N-terminal region.
Also the authors proposed that the restricted mobility in the
N-terminal region may arise from transient interchain interac-
tions, suggesting that the N-terminal KTK(E/Q)GV repeats
may serve as initiation sites for aggregation in mouse α-
synuclein [16]. These studies provided novel data on confor-
mational dynamics of α-synuclein based on species
specificity.
Very recent studies indicated that the segment residues 38
to 94 adopt mainly β-sheet conformation, with a fibrillar core
and residues 15–20 from the N-terminus showed a rigid
ordered β-sheet [17]. Schwalbe et al. [18] reported that
polyproline II plays an important role in aggregation-
nucleation sites, indicating that this region is important for
aggregation.
It is still puzzling to understand the mode (antiparallel or
parallel) of α-synuclein self-assembly and the role of exact
alignment of the central hydrophobic region folding of α-
synuclein. Further, Jiang et al. [19] studied α-synuclein as-
sembly using with or without the incorporation of artificial
leucine zippers. The studies indicated that Zips can accelerate
filament assembly in both the parallel and antiparallel
fashions. Further, the results also indicated that the central
hydrophobic region is not essential for precise alignment. The
results also suggested that α-synuclein can assemble in both
parallel and antiparallel modes. These studies provide a new
clue in conformation dynamics of α-synuclein.
α-Synuclein Modeling Data: Different Theories and Models
α-Synuclein consists of three major domains: the N-terminal
region (residues 1–65), the non-A-beta-amyloid component
(NAC) region (residues 65–95), and the C-terminal region
(residues 95–140). The N-terminal region is characterized by
a lipid-binding domain similar to apolipoprotein domains
which forms amphipathic α-helices [20]. The NAC domain
presents high propensity to undergo conformational change
from random coil to β-sheet leading to amyloid fibril forma-
tion. Both the N-terminal and NAC region present six to seven
imperfect repeats of the KTKEGV motif, which has lipid
association property [21]. The C-terminal region has no de-
fined conformational state and only presents a low hydropho-
bicity and negative net charge (due to the presence of acidic
amino acids) [22].
As mentioned earlier, three familial PD mutations namely
A30P, E46K, and A53T are found to be located in the N-
terminal domain and influence α-synuclein misfolding, ag-
gregation, and polymorphism in fibrillation [4, 5, 23]. Still it is
not clear how these familial mutations affect the domain
specific folding behavior of α-synuclein. This raises the fun-
damental issues on how familial PD mutations can influence
domain specific folding behavior. And are they thermodynam-
ically favorable? If we can understand the above issues, it is
possible to develop a favorable conformation through small
molecules which leads for future drug discovery. We used
bioinformatics tools to understand the folding complexity of
α-synuclein. The data on secondary conformations, solvent
accessibility, disorder structure prediction, 3D predicted
models, Ramachandran plot, and energy change per residue
analysis are developed.
(i) The NetSurfP secondary structure prediction (Fig. 1a, b)
method is used to understand the possible conformations in
wild-type (WT) and α-synuclein mutants [24]. WT α-
synuclein presents lower alpha helix propensity values at
residues 34–52, 93–105, and 116–120. E46Kmutation, which
involves the substitution of glutamate (E) for lysine (K) at
position 46, shows higher α-helix propensity value. This
change suggests that substitution of negatively charged (E)
for positively charged (K) could favor α-helix conformation
around residue position 46. Further, at this site, there is a
decrease in β-sheet propensity around residues (46–59) com-
pared to WT α-synuclein. Random coil propensity increases
only for E46K mutation at residues 47–54. There are no
significant localized changes in other analyzed PD mutations
(A30P and A53T).
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(ii) Relative solvent accessibility (RSA) analysis (Fig. 1b)
indicates the extent of exposure and burial of residues when a
protein folds into a 3D structure [24]. The NetSurfP RSA
analysis is used to assess which α-synuclein domains are
prone to adopt a folded or misfolded state. Results indicate
that the C-terminal region is highly exposed region, whereas
the N- and NAC regions present the buried residue regions.
These observations are in agreement with studies on α-
synuclein core region (residues 31–101) which is protease
resistant [25]. This raises the question if the NAC domain is
Fig. 1 a Secondary structure prediction for WTand mutant α-synuclein.
All mutant predictions were superimposed over WT α-synuclein (blue
bars) to understand how mutations influence α-synuclein structural con-
formation. bRelative protein surface accessibility per amino acid residue.
Highest relative solvent accessibility is observed at the C-terminal do-
main. Secondary structure prediction and relative solvent accessibility
prediction were obtained from the NetSurfP web server (http://www.cbs.
dtu.dk/services/NetSurfP/)
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the most likely region where α-synuclein folding may start.
RSA analysis is done for WT and mutant α-synuclein amino
acid sequence and no changes are observed.
(iii) Predicted protein disordered regions give an estimation of
residue segments of the peptide chain that do not adopt a stable
conformational state [26]. These unstructured regions are essen-
tial for protein structure predictions and functionality. Intrinsic
disordered segments in proteins also may be involved in func-
tional roles such as molecular recognition, cell signaling, tran-
scription, and translation [26]. Disordered regions inα-synuclein
are determined using the DISOclust system [27]. Figure 2 dem-
onstrates that the predicted disordered regions inα-synuclein are
found at the N-terminal domain (1–7 residues) and in the C-
terminal domain (residues 95–140). The NAC region does not
present any disordered conformation.
The FoldIndex analysis (Fig. 3) predicts that α-synuclein
presents only one disordered region in residues 97–140, with
an unfoldability value of 0.053 and a phobic value of 0.455.
α-Synuclein unfolded region is characterized by low hydro-
phobicity and high charge value contributing to the lack of
folding at the C-terminal region [28]. This result is consistent
with the predicted disordered region from the DISOclust
disordered prediction using a different algorithm. The three
mutations do not change the FoldIndex pattern of synuclein.
(iv) I-Tasser and PSIPRED automated structure modeling
servers used to generate WT, lipid-bound, and α-synuclein mu-
tants predicted 3D structural models [29–31]. Figure 4(a) dem-
onstrates that when α-synuclein binds to lipid, then it presents
two major α-helices at the N-terminal region of the protein.
Furthermore, predicted lipid-associated α-synuclein presents
two alpha helices joined by a turn similar to the helix-turn-
helix structural motif. This structural motif is considered a tran-
scription factor that enables DNA binding, consistent along with
experimental studies reporting α-synuclein has a propensity to
bind to DNA molecule [32]. Interestingly, the repeat hexamer
motif (KTK(E/Q)GV) is found in the same residue region in-
volved in α-helix formation of the predicted lipid-bound synu-
clein. This observation agrees with reported α-synuclein lipid
Fig. 2 DISOclust prediction of
disorder regions in α-synuclein.
The predictor score is plotted
against the residue number. The
threshold is 0.5 and residues
above this value are considered
disordered. Residues from 95 to
140 present a higher confidence
value for the predicted disordered
region
Fig. 3 α-Synuclein FoldIndex plot with window size 51. Prediction tool
was used to predict if a given protein is intrinsically unfolded. α-Synu-
clein presents an unfolded region at the C-terminal domain (residues 97–
140), with unfoldability value of 0.053 (charge 0.064, phobic 0.455)
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binding at the N-terminal and NAC domain [20]. Free state α-
synuclein model (Fig. 4(b)) presents four helical structures at the
N-terminal region and β-sheet strands at the NAC region. The
predicted structural model for free stateα-synuclein presents two
distinct structural motifs: helix-loop-helix and beta hairpin. The
helix-loop-helix and beta hairpin are also found close to the
KTK(E/Q)GV sequence repeats at the N- and C-terminal re-
gions. The NAC region presents antiparallel beta strands, which
are in agreement with reported α-synuclein β-sheet-rich core
region (residues 38–94) [17]. The C-terminal region remains
unfolded in predicted structural models, lipid-bound, and free
α-synuclein suggesting that residues at the C-terminal do not
play a major role in α-synuclein folding pattern. Studies have
reported that α-synuclein fibrillation is blocked when the C-
terminal is removed [33, 34]. If presence of the C-terminal
restrains fibrillation of α-synuclein, what residue and conditions
are necessary for these interactions to remain and maintain the
natively unfolded structure of α-synuclein?
(v) PROCHECK Ramachandran plot (RP) (Fig. 5) is used as
tool to understand if the predicted lipid-bound, free WT, and α-
synuclein mutant structures have any backbone conformation
preference [35]. The RP for the lipid-bound structure indicates
that there is a strong bias to adopt a helical conformation, and no
nonglycine residues are found in the disallowed regions of the
plot suggesting no conformational constrain. In contrast, the RP
for the free state synuclein is not biased to adopt any specific
conformation; a significant number of residues is found in theα-
helix and β-sheet regions of the plot. Additionally, nonglycine
residues (Asp98 and Thr64) are found in the disallowed regions,
indicating conformational constrains at the NAC and C-terminal
domain. A53TRP does not present any conformational constrain
in comparison to free andmutatedα-synuclein structures. On the
other side, it is important to highlight that both A30P and E46K
structures present conformational constrains at the N- and C-
terminal domains.
Overall, the RP analysis indicates that the lipid-bound and
mutant A53T α-synuclein structural model present no residues
in disallowed regions, which suggests stability. This raises the
question of whether formation of lipid α-synuclein complex and
mutation A53T inα-synuclein enhance favorable conformations
to aggregate.
(vi) Figure 6 presents the energy change per residue analysis
by FoldX [36–38]. The results indicate that lipid-bound α-
synuclein present the lowest energy change per residue at the
NACdomain (residues 65–92). TheN-terminal (residues 35–47)
and C-terminal domain (residues 92–135) of lipid-bound α-
synuclein presents the highest energy change per residue in
comparison to the C-terminal of free state and mutant α-
synuclein structure. When comparing all the studied structures,
the C-terminal domain seems to be the most unstable domain
since it presents the highest energy change values per residue. In
contrast, the NAC domain is the most stable domain with the
lowest energy change values per residue. Residue energy change
values at the NAC domain indicate residue interactions at this
region may lead to stable conformation. Furthermore, it seems
that mutations at the N-terminal domain reflect an unfavorable
thermostability effect at the C-terminal domain. Overall, α-
synuclein energy change per residue pattern presents a varied
energy landscape with very low energy minima peaks in the
middle of the chain and very high-energy peaks at the end of the
chain. The assorted distribution of high and minima energy
values along the peptide chain explains the conformational plas-
ticity of α-synuclein when adopting a specific conformation in
the presence of a specific ligand (i.e., DNA, lipid) [39].
The energy change per residue value as seen in Fig. 7 is
summed up to the present total energy change for lipid-bound
and α-synuclein mutants against free state synuclein. For exam-
ple, the total energy change of α-synuclein mutant structures is
calculated from the free α-synuclein using the following formu-
la: (ΔΔG (change)=ΔG(MT)−ΔG(WT)). Positive total energy
change in A30P and E46K mutants indicates low stability.
However, the lipid-bound and A53T mutant total energy change
is negative. These observations indicate that the dynamic folding
behavior of α-synuclein at these states is favored at low energy
barriers. This may be the reason why α-synucleins have high
affinity for lipid binding during fibril formation and possibly
explains why A53T mutant α-synuclein fibrillates faster than
WT and other two mutant structures [40, 41]. All the above
 N-terminal (1-65)
 NAC-domain (65-95)  C-terminal (95-140)Fig. 4 a Lipid-associated α-synuclein obtained from I-Tasser
protein structure prediction server
using PDB IXQ8 as target
template alignment. b Predicted
structural model for free state α-
synuclein obtained from
PSIPRED workbench web server.
Figures are colored according to
the different protein domains: N-
terminal (red), NAC domain
(green), C-terminal (blue)
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Fig. 5 Ramachandran plot for a lipid-associated α-synuclein, b wild-type α-synuclein, c Ala30Pro mutated α-synuclein, d Glu46Lys mutated α-
synuclein, e Ala53Thr mutated α-synuclein
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studies indicate that lipid α-synuclein complex has a helix pro-
pensity, however with total low energy. The mutants caused
disordered propensities leading to faster fibrillation process. We
have to look for ligands which favor α-helicity with thermody-
namically stable conformation with low aggregation pattern.
Based on the above studies, we argue that the general con-
formational properties of α-synuclein are low compactness,
absence of globularity, low secondary structure content, and high
flexibility [42]. The structural parameter is the degree of
globularization that reflects the presence or absence of a tightly
packed core in the α-synuclein molecule. α-Synuclein is coil-
like, characterized with low intramolecular packing density.
Thus, natively unfolded proteins illustrate the absence of a
globular structure, as they lack tightly packed core under phys-
iological conditions in vitro [9, 10]. The most unambiguous
characteristic of the conformational state of a α-synuclein is the
Fig. 6 α-Synuclein energy stability per residue. Representation of the energy contribution of each residue to the stability of the protein. a Lipid-bound
α-synuclein. bWT α-synuclein. cMutant A30P α-synuclein. dMutant E46K α-synuclein. eMutant A53T α-synuclein
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hydrodynamic dimensions. Based on the hydrodynamic dimen-
sions, whether it is unfolded or has lost its noncovalent structure
can be identified [42]. This is because an essential increase in the
hydrodynamic volume is associated with the unfolding of the α-
synuclein molecule. It is also known that globular proteins
whether or not may exist in at least four different conformations,
native, molten globule, premolten globule, and unfolded, that
can discriminate the degree of compactness. α-Synuclein is
characterized by an increased intramolecular flexibility derived
from heteronuclear advanced NMR studies. Increased flexibility
of natively unfolded proteins is indirectly confirmed based on the
resistance for protease digestion [42].
Further, the amino acid sequences of these proteins indicate
that these proteins have little ability to adopt a folded structure
under physiologic conditions [42]. This is mainly attributed to
the lowmean hydrophobicity and relatively high net charge. The
high net charge induces charge-charge repulsion [42]. But the
low hydrophobicity causes less driving force for a compact
structure. It is still puzzling on the presence of many ways in
which a specific sequence can lead to the absence of a globular
structure. In α-synuclein, the isolated N-terminal region is pre-
dicted to fold. But the relevance of these characters in monomer-
ic to oligomeric and protofibrils to aggregation kinetics is still not
clear.
Probable Functions of α-Synuclein
The exact role of α-synuclein in normal cell functioning is not
known to date. Understanding the role of α-synuclein in normal
cell life might be of critical importance since disruption of its
normal function might result in neurodegeneration [43]. Several
hypotheses for the normal function of α-synuclein have been
proposed, based on its structure, physical properties, subcellular
localization, and interacting partners [44]. The primary site of α-
synuclein function is most likely presynaptic, as it can be isolated
from synaptic-membrane fractions and localizes predominantly
near and around the vesicles of the presynaptic terminal [45].
Interestingly, α-synuclein binds exclusively to acidic phospho-
lipids, especially phosphatidic acid and to vesicles with small
diameters. This may target the protein to specific subpopulations
of membranes or vesicles [46].
Though it appears that lipid binding is a broadly distributed
property of α-synuclein [47], not all cellular α-synuclein seems
to be linked to membranes, since it can also be purified from the
cytosol and nucleus as reported earlier [48]. The physical and
functional homologies of α-synuclein with 14-3-3 chaperone
proteins suggest that α-synuclein may play a role in cell signal-
ing pathways [49]. α-Synuclein stimulates protein kinase A that
phosphorylates the Ser262 and Ser356 residues of tau protein
[50], which is the major constituent of insoluble paired helical
filaments found in neurofibrillary tangles and plaque neuritis in
AD [51]. α-Synuclein is detected in axons and developing
presynaptic terminals after their formation in rat embryonic
hippocampal cells in culture, suggesting a possible role in syn-
aptic development and maintenance. α-Synuclein also seems to
contribute to neuronal differentiation. The arguments in this
direction are (a) in vivo,α-synuclein is localized in the cell body
of neuronal precursors during early embryonic development
[52], but in presynaptic terminals in postnatal and adult cortex;
and (b) a sustained increase in α-synuclein levels is observed
when rat pheochromocytoma cells (PC12) are treated with nerve
growth factor, which induces a neuronal phenotype [53]. The
involvement of α-synuclein in synaptic plasticity and neuronal
differentiation may be mediated by the selective inhibition of
phospholipase D2 by α-synuclein, since isoforms of phospholi-
pase D were shown to be implicated in cell growth and differ-
entiation [54].
However, the involvement of α-synuclein in neuronal and
synaptic development could not be confirmed in mice lacking
the α-synuclein gene homozygously, since these mice are
behaviorally normal and showed neither macroscopic nor
microscopic changes in their nervous system [55]. Hence,
Fig. 7 Total energy change for
lipid-bound and mutant α-
synuclein. Lipid-bound and
mutant α-synuclein total energy
chance per residue value was
subtracted from the total energy
change per residue value of WT
α-synuclein. Energy change per
residue values were obtained
using FoldX forcefield command
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inactivation of the α-synuclein gene does not lead to a signif-
icant neurological phenotype, although changes in dopami-
nergic electrophysiology may reflect a specific function relat-
ed to neurotransmitter release. When α-synuclein expression
is markedly reduced in cultured rat neurons or abolished in α-
synuclein knockout mice [55], the number of vesicles in the
distal pool of the presynaptic terminal is reduced indicating a
role for α-synuclein in vesicular dynamics. According to Cole
et al. [56], α-synuclein involvement in lipid metabolism can-
not be ruled out, given its propensity to bind molecules with
high hydrophobic content or exposed hydrophobic domains.
The major difficulty in understanding α-synuclein function
has been its inherent flexibility in native structure and its
altered conformation in the presence of lipids. It is not known
whether the molecules that bind to α-synuclein in vivo do so
in its membrane-associated (modular) or free (natively unfold-
ed) state, or both [56]. It also remains to be investigated
whether the interactions of α-synuclein with membranes in-
fluence its self-assembly and filament formation. The func-
tional biology of synuclein needs to be further explored.
There are limited studies on α-synuclein phylogenetic con-
servation regions that provide guidance for understanding the
structure and function of this disordered protein. Yuan and
Zhao [57] provided insight on specific evolutionary relation-
ship across all three synuclein subfamilies (alpha, beta, and
gamma). The analysis of 253 synuclein sequences from 73
organisms presented a highly conserved N-terminal, while no
global conservation is observed within the C-terminal in all
the synuclein subfamilies. Most of the conserved residues (42
in total) are found within the 6 of the 11 repeat motif
KTK(E/Q)GV, similar to the observed motifs in apolipopro-
teins [20]. This finding suggests that conserved residues are
likely to play a structural role, however less is known about
the functional role of these repeats. Further, conservation
analysis of the synuclein subfamilies showed that some resi-
dues have evolved into group-specific residues providing
distinct functional properties to synuclein subfamilies. For
instance, the analysis revealed that His50 is 91 % conserved
only in α-synuclein subfamily. Dudzik et al. [58] studied the
functional role of this residue as metal binding by substituting
histidine for alanine at position 50 resulting in impaired cop-
per binding at this position.
Levitan et al. [59] indicated that conserved C-terminal
negatively charged residues play a protective role against
rapid α-synuclein aggregation. The experimental results
showed that α-synuclein with a truncated C-terminal exhibit-
ed a faster aggregation rate due to the absence of acidic
residues, whereas α-synuclein phosphorylated at Ser129
showed a slower aggregation rate as a result of increased
negative charge at the C-terminal. Alignment of 15 homolo-
gous α-synuclein sequences from different mammals demon-
strated complete conservation of Ser129 and negatively
charged residues at the C-terminal. This is in agreement with
Sato et al. [60] who reported that Ser129 is the site where 90%
of the aggregated α-synuclein gets phosphorylated. Thus,
these studies indicate the role of conserved negatively charged
residues in the modulation of α-synuclein aggregation.
Aggregation of α-Synuclein
α-Synuclein is natively unfolded protein and tends to aggre-
gate into fibrils. Though the mechanism of aggregation is not
understood, few pathways are mapped. The mechanism of
aggregation is multifaceted in nature and understanding ag-
gregation has a therapeutic potential [61]. The native confor-
mation of synuclein in the human brain is not known. A recent
study indicated that synuclein exists in metastable conformers
and stable monomer in the human brain [62].
α-Synuclein Monomer
α-Synuclein is located in synaptic nerve terminals in the
normal brain [62, 63]. However, its functional structure at this
location is less clear as it may exist in an exchangeable soluble
cytosolic pool of monomeric α-synuclein and a vesicle-
associated pool, where the latter may contain helical mono-
meric conformers as well as oligomeric species [56]. A range
of posttranslational modifications of monomeric α-synuclein
like C-terminal truncations, phosphorylations, ubiquitin-
immunoreactive inclusions, and oxidative modifications have
been detected in pathological nerve cell lesions [64]. Further,
extrinsic factors affecting the aggregation of monomeric α-
synuclein comprise metal ions, etc., as discussed later.
α-Synuclein Oligomers
When α-synuclein monomers start to associate, we envision
the existence of an initial population of oligomers that is in
equilibrium with the monomers [65–67]. In contrast to the
monomers, these amyloid-type oligomers display distinct
structural features that can be visualized by oligomer-
specific antibodies [68]. They are enriched in cross-β struc-
ture and have been described as about 4 nm in height and
20 nm wide [69], but their morphology appears heteroge-
neous. The low amount of the oligomers present during α-
synuclein aggregation and their transient nature have made
their characterization difficult but size estimates based on gel
filtration are in the range of 140–800 kDa [68], and antibody
binding demonstrates that they display some epitopes exclu-
sive for oligomers and some shared with filaments [68]. The
protocols for the preparation of oligomers have allowed the
generation of large amounts of oligomers that share a range of
biophysical characteristics with the abovementioned oligo-
mers [70]. These methods are based on the rapid reconstitu-
tion of lyophilized α-synuclein to a high concentration in
buffer at low temperature for a relatively short time period
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followed by filtration and gel filtration. It will be important to
compare these so-called fast oligomers to the less abundant
oligomers formed during the normal slow aggregation of
recombinant α-synuclein but also to the α-synuclein in brain
tissue that displays a reduced solubility. Such in vivo oligo-
mers have previously only been indicated by the presence of
α-synuclein species in the soluble fraction of brain extracts
that displays resistance to depolymerization [71]. A study with
atomic force microscopy investigation of glial cytoplasmic
inclusions isolated from unfixed brain tissue may have re-
vealed novel insight into the nature of brain α-synuclein
oligomers [72]. The purified glial cytoplasmic inclusions con-
taining both filamentous and granular material were solubi-
lized in mild detergents leaving α-synuclein-positive annular
particles. The sizes of the particles did depend on the detergent
used as did the size of recombinant monomeric α-synuclein
and they can accordingly not directly be compared with
in vitro formed oligomers made without detergents.
However, this provocative study suggests that annular α-
synuclein oligomers are associated to the glial cytoplasmic
inclusions or even that the filaments may be composed of
annular oligomers joined by hydrophobic interactions that are
sensitive to mild detergents.
α-Synuclein Filaments
Filaments develop during the aggregation process when the
oligomers are consumed [73]. The in vitro formed filaments
are 8–10 nm in height and 10 nm wide as determined by
atomic force microscopy and by electron microscopy, respec-
tively [6] They have a straight appearance [6, 69] and possess
a cross-β structure as demonstrated by dye binding properties,
microscopy, and spectroscopy [69]. The in vitro formed α-
synuclein filaments are similar to th filaments extracted from
Parkinson’s disease and Lewy body dementia brains in terms
of diameter [6, 2]. This contrasts those from multiple system
atrophy brain tissues that are of a larger diameter [74] which
may be due to coating materials including proteins [75].
However, washing of those filaments revealed a core filament
of similar diameter as the in vitro formed filaments, suggesting
a heavy coating by filament-associated proteins [75]. The
existence of such coat proteins is corroborated by the discov-
ery of several filament-binding proteins [76, 68]. This raises
the question as to whether α-synuclein-positive filaments in
brain inclusions consist of homopolymers of α-synuclein
heteropolymers wherein or whereupon α-synuclein aggregate
binding proteins are incorporated. The filaments formed
in vitro are usually straight and unbranched and similarly
structured filaments are likely to exist in vivo as judged from
electron microscopic studies of LB and glial cytoplasmic
inclusions [2, 77]. The electron micrographs display mesh-
like α-synuclein-positive structures with frequent branching
[68, 69]. The branchingα-synuclein aggregates may represent
heteropolymers where the α-synuclein aggregate binding pro-
teins form the sites for elongation in more directions.
Moreover, it suggests that several protein factors may be
involved in the regulation of α-synuclein aggregation
in vivo and represent effectors for the possible toxicity of α-
synuclein aggregates.
Metals as Biofactors Modulating α-Synuclein Conformation
and Aggregation
Essential metals like Cu, Fe, Mg, etc. have a pivotal role in
brain function. Any elevation or decrease in these metal ions
leads to neuronal dysfunction. There are lines of evidence
regarding the elevation of Cu and Fe in neurodegenerative
disorders and their significant role in neuropathology in the
brain [78–81]. Also lines of evidence suggest that metals act
as etiological factors in aggregation and thus gained central
role neurodegeneration [82, 83]. Herein we summarized the
data on the interaction of metals with α-synuclein. A number
of metals have been shown to stimulate α-synuclein aggrega-
tion in vitro, including Al3+, Fe3+, Co3+,Mn2+, Ca2+, and Cu2+
[10]. Al3+ displays the most pronounced effect on increasing
the α-synuclein aggregation [10]. Interactions of metals with
the acidic C-terminus have been proposed as a model for these
effects [10]. Mg2+ inhibits spontaneous as well as iron-
induced α-synuclein aggregation [84], suggesting that some
metals can counteract the effect of others. Further studies
showed that redox-active metal ions such as iron (Fe) and
copper (Cu) are known to enhance α-synuclein fibrillogenesis
in a differential pattern and hypothesized that protein oligo-
mers have a dynamic function in neuronal cell dysfunction
[65, 85]. Studies from Bharathi and Rao [86] reported the
binding efficiency of Cu and Fe to α-synuclein by fluores-
cence studies. They found that Cu and Fe showed a differen-
tial binding pattern toward α-synuclein (wild-type and A30P,
A53T, and E46K mutant forms) as revealed by intrinsic tyro-
sine fluorescence, thioflavin-T fluorescence, and 1-anilino-8-
naphthalenesulfonate-binding studies. The experimental data
may be useful in understanding the hierarchy of metals bind-
ing to α-synuclein. Further, Bharathi et al. [87] reported that
Cu (II) and Fe (III) selectively and differentially induced the
formation of discrete α-synuclein fibrillar species. Cu (II) has
induced thin long network-like fibrils with the wild type of α-
synuclein, while the mutant showed amorphous aggregates
with no fibrillar forms. Fe (III) induced short and thick fibrils
with both wild and mutant forms and similar to α-synuclein
fibrils incubated without metal ion. These studies provided a
new clue that metals induce differential polymorphic aggre-
gates in α-synuclein. Also Bharathi and Rao [88] provided
new evidence on thermodynamic imprinting of stoichiometry
binding of metals to α-synuclein. α-Synuclein monomer
(wild and mutant forms) titrated by Cu (II) showed two
binding sites, with an apparent and with Fe (III) single binding
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site. Altogether, the data prove conclusively that Cu (II) has
preferentially two sites of binding to α-synuclein. Fe (III)
possesses a single binding site and has high binding efficien-
cy. And Cu (II) is enthalpically driven with large entropy than
Fe (III). Presumably, these findings might lead to a new
conceptual scheme to understand the hierarchy of metal-α-
synuclein interactions, which based on the principles of ther-
modynamics, thus reflects a better mode to understand the
binding properties of α-synuclein with metals [88]. The study
of Bharathi et al. [85] reported an independent Cu binding site
in both the lipid-binding N-terminal domain and the highly
acidic C-terminal domain of α-synuclein. The NMR studies
clearly showed that Cu binds at the N-terminal and the histi-
dine sites, as well as the sites in the C-terminal tail. Binolfi
et al. [90] reported the binding features of the divalent metal
ions Fe (II), Mn (II), Co (II), and Ni (II) and their effects onα-
synuclein fibril formation. The results indicated that the diva-
lent metal ions bind preferentially and with low affinity
(millimolar) to the C-terminus of α-synuclein. These findings
indicated a strong link between the specificity of α-synuclein-
metal (II) interactions and the enhancement of aggregation of
α-synuclein. Further, Drew et al. [91] studied the Cu (II)
binding to recombinant human α-synuclein using electron
paramagnetic resonance (EPR) spectroscopy. The study clear-
ly showed that the wild-type (wt) α-synuclein has a binding
stoichiometric Cu (II) via two N-terminal binding modes at
pH 7.0. Further studies using electron spin-echo envelope
modulation (ESEEM) indicated that α-synuclein confirmed
the second binding mode at pH 7.4 through the coordination
of His50. However, at acidic pH 5.0, His50-anchored Cu (II)
binding is diminished, but the {NH2, N (−), beta-COO (−),
H2O} binding still persisted in conjunction with another two
binding modes. In total, the studies showed that there are four
Cu (II) binding modes within the pH range of 5.0–7.4. Lee
et al. [92] studied the Trp4 fluorescence decay kinetics and
reported that Cu (II) binds tightly (Kd~100 nM) near the N-
terminus at pH 7. Further studies with histidine mutant
showed that a histidine imidazole is not a ligand in this high-
affinity site. Kostka et al. [93] studied the role of Fe (III) at low
micromolar concentrations and found that it increases aggre-
gation and also favors the formation of larger oligomers
(“intermediate II”). These oligomer species will seed fibril
formation. Interesting findings from this study are that Fe
(III)-induced oligomers are SDS resistant and could form
ion-permeable pores in a planar lipid bilayer. These results
provide insight on the role of ferric iron and of toxic oligomer
species in PD. A study from Liu and Franz [94] tried to
understand the phosphorylation-dependent metal binding by
α-synuclein peptide fragments. They have studied the metal-
binding properties of synthetic peptides and phosphopeptides
of residues 119–132 of the C-terminal, polyacidic stretch of
human α-synuclein, with the sequence Ac-Asp-Pro-Asp-Asn-
Glu-Ala-Tyr-Glu-Met-Pro-Ser-Glu-Glu-Gly (α-synuclein
119–132). The peptide pY125, which is a tyrosine, is replaced
with phosphotyrosine. The interaction of other metal ions is
studied by electrospray ionization mass spectrometry, which
confirmed that pY125 (phosphorylated tyrosine-125) is selec-
tive for trivalent metal ions over divalent metal ions. The study
also indicated that Fe (III) and Al (III) induce peptide dimer-
ization through metal ion cross-links. The circular dichroism
studied provided insight that Fe (III) causes a partially folded
conformation for pY125, with no change for pS129, the
unphosphorylated analog. The studies indicated that the phos-
phorylated amino acid influences a peptide’s metal-binding
specificity and its influence on conformation. Recent studies
indicated that the phosphorylation at sites Y125 and S129
influences the metal-binding properties on synuclein [94].
These studies provide lines of evidence on the role of metals
in modulating synuclein aggregation.
Conclusions
Assuming that protein misfolding is triggered by conforma-
tional changes stabilized by protein oligomerization, an inter-
esting strategy would be to preclude the stabilization of the
misfolding or better to destabilize the monomeric intermediate
and the early oligomers. We have postulated that if small
molecules or molecular chaperones destabilize the abnormal
conformation, this might be useful to correct protein
misfolding. Considering that in most neurodegenerative dis-
orders the misfolded protein is rich in beta-sheet structure, our
focus should be mainly on the design of small molecules to
prevent and reverse beta-sheet formation (beta-sheet
breakers). The principles to manipulate protein conformation
may provide a general platform technology to design drugs for
the treatment of PD.
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